From bionic eyes to gene editing, how can we use science to bring back sight?
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
The medical regulatory authorities ride a wave of clinical studies for gene therapies.
The research is promising, but a true cure for this painful condition could be years away.
Insertion of genetic information can prompt the body to make antibody-based drugs, offering a fresh approach to treating diseases such as influenza, as well as infections like HIV.
The hope of gene therapy could be crushed by its financial burden unless there are more rational ways of paying for it, says Michael Sherman.
Gene therapy could one day be used for bodily enhancement, creating an ethical minefield for physicians, says Ellen Wright Clayton.
Gene therapy for single-gene disorders is at a pivotal period in its evolution, with continued successful development requiring tight collaboration among industry, academic, regulatory, clinical and patient communities.
Cancelling out an illness before a child is born offers the most potential benefit.
Gene tinkering opens the door to treatments for an array of diseases
Researcher and entrepreneur Luk Vandenberghe thinks he can transport genes into cells much more efficiently by improving the viral vectors that carry them.
The largest organ in the body is a prime target for gene therapy.
A permissive regulatory climate and a pragmatic approach have fostered soaring growth
A machine learning algorithm uses EEG traces to find a patient’s odds of waking
The gene targeted for its role in HIV is linked to increased severity of other infectious diseases—and has implications for learning in mice
The preliminary announcement comes in the wake of a Trump administration order that agency scientists to stop buying such tissue from humans
Research and development in medical technology is responding to transformative changes in healthcare, not only by developing new products, but by finding new ways to innovate. Singapore has a unique, well-developed healthcare and R&D ecosystem making it an ideal location to trial new systems.
The cross-species heart procedure brings human trials into view
If repeated, the feat may open the door to expanding infertility treatments
After false starts, researchers are making progress toward treating deafness with gene therapy